You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Litigation Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

✉ Email this page to a colleague

« Back to Dashboard

Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

Docket	⤷ Sign Up	Date Filed	2022-02-23
Court	District Court, D. Delaware	Date Terminated	2024-10-23
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To	Jennifer L. Hall
Patents	7,579,473; 8,877,776
Link to Docket	External link to docket

Small Molecule Drugs cited in Exelixis, Inc. v. MSN Laboratories Private Limited

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up and ⤷ Sign Up .

Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2023-12-12	167	Post Trial Brief	’s ANDA Products infringe Exelixis’ U.S. Patent No. 7,579,473, which covers cabozantinib. D.I. 331 (Final…439 patent U.S. Patent No. 11,091,439 (JTX-001) ’440 patent U.S. Patent No. …015 patent U.S. Patent No. 11,098,015 (JTX-003) ’349 patent U.S. Patent No. … claim 3 of U.S. Patent No. 11,298,349 (“the ’349 patent”). The ’349 patent is directed to a …including claim 4 of U.S. Patent No. 11,091,439 (“the ’439 patent”), claim 3 of U.S. Patent No. 11,091,440 (“	External link to document
2023-12-12	170	Proposed Findings of Fact	double-patenting reference claim. 65. U.S. Patent No. 7,579,473 (“the ’473 patent”) issued…DOUBLE PATENTING OF THE MALATE SALT PATENTS A. Claim 5 of the ’473 patent is a double-patenting…. OBVIOUSNESS-TYPE DOUBLE PATENTING OF THE MALATE SALT PATENTS .............................… A. Claim 5 of the ’473 patent is a double-patenting reference claim. ..…NONOBVIOUSNESS FOR THE MALATE SALT PATENTS OR THE ’349 PATENT...............................27	External link to document
2024-01-23	175	Post Trial Brief	’473 patent U.S. Patent No. 7,579,473 (DTX-13) ’776 patent U.S. Patent No. 8,877,776…’439 patent U.S. Patent No. 11,091,439 (JTX-1) ’440 patent U.S. Patent No. 11,091,440…’015 patent U.S. Patent No. 11,098,015 (JTX-3) ’349 patent U.S. Patent No. 11,298,349… ’439 patent, ’440 patent, ’015 patent, and ’349 Patents-in-Suit …the ’440 patent and ’015 patent would have been patentably indistinct over the ’473 patent.	External link to document
2024-01-23	176	Proposed Findings of Fact	’473 patent U.S. Patent No. 7,579,473 (DTX-13) ’776 patent U.S. Patent No. 8,877,776… ’439 patent, ’440 patent, ’015 patent, and Patents-in-Suit ’349 patent …’439 patent U.S. Patent No. 11,091,439 (JTX-1) ’440 patent U.S. Patent No. 11,091,440…’015 patent U.S. Patent No. 11,098,015 (JTX-3) ’349 patent U.S. Patent No. 11,298,349…473 compound patent issued— and they filed patent applications and received issued patents related to	External link to document
2024-10-15	186	Opinion	ESS-TYPE DOUBLE PATENTING A. Findings of Fact 1. U.S. Patent No. 7,579,473 ("the…the '439 patent, Claim 3 of the ' 440 patent, and Claim 2 of the '015 patent. (Id. ,r 6).…; '440 patent at 32 :1 6- 21; '015 patent at 32:11- 16). The '349 patent is directed…. 1998). A later patent claim is not patentably distinct from an earlier patent claim if the later …;439 patent is invalid for obviousness-type double patenting of Claim 5 of the '473 patent. (D.I	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.